Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma

Phase 1 Recruiting 15 enrolled Zhejiang University Carbiogene Therapeutics Co. Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A phase I clinical study of 4th generation chimeric antigen receptor T Cells targeting glypican-3 ( CAR-GPC3 T Cells) in patients with advanced hepatocellular carcinoma.

Timeline

Start: 2024-07-01
Primary completion: 2027-07-01
Completion: 2027-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CBG166	Unknown	—	Intravenous

Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma

Summary

Timeline

Drugs

Indications